AU2017264683B2 - Anti-PD-L1 antibodies - Google Patents

Anti-PD-L1 antibodies Download PDF

Info

Publication number
AU2017264683B2
AU2017264683B2 AU2017264683A AU2017264683A AU2017264683B2 AU 2017264683 B2 AU2017264683 B2 AU 2017264683B2 AU 2017264683 A AU2017264683 A AU 2017264683A AU 2017264683 A AU2017264683 A AU 2017264683A AU 2017264683 B2 AU2017264683 B2 AU 2017264683B2
Authority
AU
Australia
Prior art keywords
antibody
antigen
sequence
seq
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017264683A
Other languages
English (en)
Other versions
AU2017264683A1 (en
Inventor
Ramesh Baliga
Bruce Keyt
Leonard George Presta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IGM Biosciences Inc
Original Assignee
IGM Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IGM Biosciences Inc filed Critical IGM Biosciences Inc
Publication of AU2017264683A1 publication Critical patent/AU2017264683A1/en
Application granted granted Critical
Publication of AU2017264683B2 publication Critical patent/AU2017264683B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70532—B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AU2017264683A 2016-05-09 2017-05-09 Anti-PD-L1 antibodies Ceased AU2017264683B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662333643P 2016-05-09 2016-05-09
US62/333,643 2016-05-09
PCT/US2017/031791 WO2017196867A1 (en) 2016-05-09 2017-05-09 Anti-pd-l1 antibodies

Publications (2)

Publication Number Publication Date
AU2017264683A1 AU2017264683A1 (en) 2018-11-01
AU2017264683B2 true AU2017264683B2 (en) 2024-02-29

Family

ID=58710168

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017264683A Ceased AU2017264683B2 (en) 2016-05-09 2017-05-09 Anti-PD-L1 antibodies

Country Status (15)

Country Link
US (3) US10954302B2 (enExample)
EP (1) EP3455257B1 (enExample)
JP (1) JP6979971B2 (enExample)
KR (1) KR102343742B1 (enExample)
CN (1) CN109311985B (enExample)
AU (1) AU2017264683B2 (enExample)
CA (1) CA3021669A1 (enExample)
DK (1) DK3455257T3 (enExample)
ES (1) ES2899361T3 (enExample)
HU (1) HUE055972T2 (enExample)
IL (1) IL262295B2 (enExample)
PL (1) PL3455257T3 (enExample)
PT (1) PT3455257T (enExample)
SG (1) SG11201809336QA (enExample)
WO (1) WO2017196867A1 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150131269A (ko) 2013-03-15 2015-11-24 제넨테크, 인크. Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
CN105722855B (zh) 2013-09-05 2021-04-23 Igm生物科学股份有限公司 恒定链经修饰的双特异性五价和六价Ig-M抗体
WO2015120474A1 (en) 2014-02-10 2015-08-13 Igm Biosciences, Inc. Iga multi-specific binding molecules
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
EP4011910A1 (en) 2014-04-03 2022-06-15 IGM Biosciences, Inc. Modified j-chain
CN106604933B (zh) 2014-07-11 2021-08-10 文塔纳医疗系统公司 抗pd-l1抗体及其诊断用途
PT3247728T (pt) 2015-01-20 2020-07-16 Igm Biosciences Inc Moléculas de ligação do recetor da superfamília do fator de necrose tumoral (fnt) e utilização das mesmas
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
KR102357312B1 (ko) 2015-03-04 2022-02-03 아이쥐엠 바이오사이언스 인코포레이티드 Ｃｄ20 결합 분자 및 그의 용도
MA42971A (fr) 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
WO2016154593A1 (en) 2015-03-25 2016-09-29 Igm Biosciences, Inc. Multi-valent hepatitis b virus antigen binding molecules and uses thereof
AU2016249404B2 (en) 2015-04-17 2021-01-21 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
ES2819870T3 (es) 2015-09-30 2021-04-19 Igm Biosciences Inc Moléculas de unión con cadena J modificada
PT3355913T (pt) 2015-09-30 2024-12-18 Igm Biosciences Inc Moléculas de ligação com cadeia j modificada
WO2017196867A1 (en) * 2016-05-09 2017-11-16 Igm Biosciences, Inc. Anti-pd-l1 antibodies
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
BR112019000071A2 (pt) 2016-07-07 2019-07-02 Bolt Biotherapeutics Inc conjugados adjuvantes de anticorpo
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
CA3055790A1 (en) 2017-04-07 2018-10-11 Igm Biosciences, Inc. Modified human igm constant regions for modulation of complement-dependent cytolysis effector function
BR112019021520A2 (pt) 2017-04-14 2020-08-04 Tollnine, Inc. oligonucleotídeo, composto, polinucleotídeo imunomodulador, composição, conjugado, método para modular um receptor, método de tratamento de um tumor, método de tratamento de câncer, método para tratar um tumor, método de prevenção de câncer, método para induzir uma resposta imune
CN110914302A (zh) 2017-06-01 2020-03-24 赛托姆克斯治疗学股份有限公司 可活化抗pdl1抗体及其使用方法
US11673954B2 (en) 2017-11-17 2023-06-13 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against PD-L1
WO2019109974A1 (zh) * 2017-12-06 2019-06-13 正大天晴药业集团南京顺欣制药有限公司 抗pd-l1抗体及其抗原结合片段
CN109970856B (zh) 2017-12-27 2022-08-23 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
MX2020007406A (es) * 2018-01-10 2020-09-14 Jiangsu Hengrui Medicine Co Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo.
EP3740509A4 (en) * 2018-01-17 2022-06-22 Apexigen, Inc. Anti-pd-l1 antibodies and methods of use
CN111787951B (zh) 2018-03-01 2025-06-17 Igm生物科学股份有限公司 影响IgM血清半衰期的IgM Fc和J链突变
TWI756621B (zh) * 2019-01-25 2022-03-01 大陸商信達生物製藥（蘇州）有限公司 新型雙特異性抗體分子以及同時結合pd-l1和lag-3的雙特異性抗體
MX2021010116A (es) * 2019-02-21 2021-09-23 Eucure Beijing Biopharma Co Ltd Anticuerpo anti-pd-l1 y uso de este.
EP3937984A1 (en) 2019-03-15 2022-01-19 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
JP2022544405A (ja) * 2019-08-15 2022-10-18 アイジーエム バイオサイエンシズ インコーポレイテッド 免疫刺激性多量体型結合分子
CN110746493A (zh) * 2019-09-06 2020-02-04 中国药科大学 一种pd-l1拮抗剂多肽及其应用
CN113121686B (zh) * 2019-12-31 2025-12-02 迈威(上海)生物科技股份有限公司 抗pd-l1抗体及其应用
IL295759A (en) 2020-02-28 2022-10-01 Tallac Therapeutics Inc Transglutaminase mediated coupling
JP2023522962A (ja) 2020-04-22 2023-06-01 アイジーエム バイオサイエンシズ インコーポレイテッド Ｐｄ－１アゴニスト多量体結合分子
CN113754775A (zh) * 2020-06-02 2021-12-07 三生国健药业（上海）股份有限公司 一种抗pd-l1和her2的双特异性抗体
WO2021257124A1 (en) 2020-06-18 2021-12-23 Genentech, Inc. Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
US20230058162A1 (en) * 2020-07-27 2023-02-23 Igm Biosciences, Inc. Multimeric coronavirus binding molecules and uses thereof
KR20250140647A (ko) * 2020-08-03 2025-09-25 난트셀, 인크. Il-15 초작용제에 대한 약물-특이적 약동학 검정
CN118871463A (zh) 2021-07-28 2024-10-29 基因泰克公司 用于治疗癌症的方法和组合物
MX2024001877A (es) 2021-08-10 2024-02-28 Kymab Ltd Tratamiento de dermatitis atopica.
WO2023056403A1 (en) 2021-09-30 2023-04-06 Genentech, Inc. Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
CN113943371B (zh) * 2021-11-01 2023-05-05 达石药业(广东)有限公司 一种抗her2/抗pd-l1双功能抗体及其应用
WO2023178253A2 (en) * 2022-03-18 2023-09-21 Igm Biosciences, Inc. Use of a multimeric anti-pd-l1 binding molecule in combination with a monoclonal antibody therapy
JP2025523387A (ja) 2022-06-07 2025-07-23 ジェネンテック， インコーポレイテッド 抗ｐｄ－ｌ１アンタゴニストおよび抗ｔｉｇｉｔアンタゴニスト抗体を含む、肺がん治療の有効性を判定するための方法
JP2026517051A (ja) * 2023-01-18 2026-05-28 エルピサイエンス・（スージョウ）・バイオファーマ，リミテッド 抗ｐｄｌ１単一ドメイン抗体、融合タンパク質及びその使用
US20240294651A1 (en) 2023-01-30 2024-09-05 Kymab Limited Antibodies

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013079174A1 (en) * 2011-11-28 2013-06-06 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
WO2015112805A1 (en) * 2014-01-23 2015-07-30 Regeneron Pharmaceuticals, Inc. Human antibodies to pd-l1
WO2015181342A1 (en) * 2014-05-29 2015-12-03 Spring Bioscience Corporation Pd-l1 antibodies and uses thereof
WO2016000619A1 (en) * 2014-07-03 2016-01-07 Beigene, Ltd. Anti-pd-l1 antibodies and their use as therapeutics and diagnostics

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20050014932A1 (en) 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
AU2005304973A1 (en) 2004-11-05 2006-05-18 Palingen, Inc. Antibody induced cell membrane wounding
MX356367B (es) * 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
WO2013120012A2 (en) 2012-02-08 2013-08-15 Igm Biosciences Inc. Cdim binding proteins and uses thereof
CN105722855B (zh) 2013-09-05 2021-04-23 Igm生物科学股份有限公司 恒定链经修饰的双特异性五价和六价Ig-M抗体
WO2015120474A1 (en) 2014-02-10 2015-08-13 Igm Biosciences, Inc. Iga multi-specific binding molecules
EP4011910A1 (en) * 2014-04-03 2022-06-15 IGM Biosciences, Inc. Modified j-chain
SG10201901057UA (en) * 2014-08-05 2019-03-28 Cb Therapeutics Inc Anti-pd-l1 antibodies
PT3247728T (pt) 2015-01-20 2020-07-16 Igm Biosciences Inc Moléculas de ligação do recetor da superfamília do fator de necrose tumoral (fnt) e utilização das mesmas
KR102357312B1 (ko) 2015-03-04 2022-02-03 아이쥐엠 바이오사이언스 인코포레이티드 Ｃｄ20 결합 분자 및 그의 용도
WO2016154593A1 (en) 2015-03-25 2016-09-29 Igm Biosciences, Inc. Multi-valent hepatitis b virus antigen binding molecules and uses thereof
AU2016249404B2 (en) 2015-04-17 2021-01-21 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
ES2819870T3 (es) * 2015-09-30 2021-04-19 Igm Biosciences Inc Moléculas de unión con cadena J modificada
PT3355913T (pt) 2015-09-30 2024-12-18 Igm Biosciences Inc Moléculas de ligação com cadeia j modificada
WO2017196867A1 (en) * 2016-05-09 2017-11-16 Igm Biosciences, Inc. Anti-pd-l1 antibodies
CA3030659A1 (en) 2016-07-20 2018-01-25 Igm Biosciences, Inc. Multimeric gitr binding molecules and uses thereof
AU2017299608A1 (en) 2016-07-20 2019-02-07 Igm Biosciences, Inc. Multimeric CD137/4-1BB binding molecules and uses thereof
US20190330374A1 (en) 2016-07-20 2019-10-31 Igm Biosciences, Inc. Multimeric ox40 binding molecules and uses thereof
US20190338041A1 (en) 2016-07-20 2019-11-07 Igm Biosciences, Inc. Multimeric cd40 binding molecules and uses thereof
CA3055790A1 (en) 2017-04-07 2018-10-11 Igm Biosciences, Inc. Modified human igm constant regions for modulation of complement-dependent cytolysis effector function
EP3759229A4 (en) 2018-02-26 2021-12-29 IGM Biosciences Inc. Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer
CN111787951B (zh) 2018-03-01 2025-06-17 Igm生物科学股份有限公司 影响IgM血清半衰期的IgM Fc和J链突变
AU2019368289A1 (en) 2018-10-23 2021-04-29 Igm Biosciences, Inc. Multivalent IgM- and IgA-Fc-based binding molecules
US20220106398A1 (en) 2019-02-08 2022-04-07 Igm Biosciences, Inc. Anti-gitr antigen-binding domains and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013079174A1 (en) * 2011-11-28 2013-06-06 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
WO2015112805A1 (en) * 2014-01-23 2015-07-30 Regeneron Pharmaceuticals, Inc. Human antibodies to pd-l1
WO2015181342A1 (en) * 2014-05-29 2015-12-03 Spring Bioscience Corporation Pd-l1 antibodies and uses thereof
WO2016000619A1 (en) * 2014-07-03 2016-01-07 Beigene, Ltd. Anti-pd-l1 antibodies and their use as therapeutics and diagnostics

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
NAOYA MAEKAWA ET AL: "Expression of PD-L1 on Canine Tumor Cells and Enhancement of IFN-[gamma] Production from Tumor-Infiltrating Cells by PD-L1 Blockade", PLOS ONE, vol. 9, no. 6, 10 June 2014 (2014-06-10), pages e98415 *
PATRICK J. MEDINA ET AL: "PD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune Responses", PHARMACOTHERAPY : THE JOURNAL OF HUMAN PHARMACOLOGY AND DRUG THERAPY, vol. 36, no. 3, 20 March 2016, pages 317 - 334 *
ROSENBERG JONATHAN E ET AL: , THE LANCET, THE LANCET PUBLISHING GROUP, GB, vol. 387, no. 10031, 4 March 2016 (2016-03-04), pages 1909 - 1920, XP029530539, ISSN: 0140-6736, DOI: 10.1016/S0140-6736(16)00561-4 *

Also Published As

Publication number Publication date
CA3021669A1 (en) 2017-11-16
SG11201809336QA (en) 2018-11-29
EP3455257B1 (en) 2021-09-22
IL262295B2 (en) 2023-09-01
AU2017264683A1 (en) 2018-11-01
JP6979971B2 (ja) 2021-12-15
CN109311985B (zh) 2022-09-30
EP3455257A1 (en) 2019-03-20
PL3455257T3 (pl) 2022-01-17
IL262295A (en) 2018-12-31
JP2019519492A (ja) 2019-07-11
IL262295B1 (en) 2023-05-01
CN109311985A (zh) 2019-02-05
PT3455257T (pt) 2021-12-06
ES2899361T3 (es) 2022-03-11
KR102343742B1 (ko) 2021-12-24
US10954302B2 (en) 2021-03-23
HUE055972T2 (hu) 2022-01-28
KR20190003989A (ko) 2019-01-10
WO2017196867A1 (en) 2017-11-16
DK3455257T3 (da) 2021-11-01
US20210163600A1 (en) 2021-06-03
US20240002514A1 (en) 2024-01-04
US20190338031A1 (en) 2019-11-07

Similar Documents

Publication Publication Date Title
US20240002514A1 (en) Anti-pd-l1 antibodies
CN111629754B (zh) 不引起显著红血细胞凝集的抗cd47抗体
CN107406503B (zh) Cd47抗体、方法和用途
KR102276974B1 (ko) 비-혈소판 및 비-적혈구 세포 격감성 cd47 항체 및 이를 이용하는 방법
KR102338833B1 (ko) Cd47 항체 및 그 사용 방법
CA2977621C (en) Antibody binding to tfpi and composition comprising the same
CA2928043A1 (en) Anti-podocalyxin antibodies and methods of using the same
CN114057876B (zh) Cd47抗体及其应用
JP2022550121A (ja) Ｌｉｆに特異的な結合分子及びその使用
JP2023545742A (ja) 抗ｔｒｏｐ－２抗体、その抗原結合断片又はその変異体、及びそれらの医学的使用
HK1261643B (en) Anti-pd-l1 antibodies
HK40071904A (en) Cd47 antibody and the use thereof
HK40071904B (en) Cd47 antibody and the use thereof
JP2026504831A (ja) ＴＧＦβ１結合分子、ＧＡＲＰ－ＴＧＦβ１結合分子及びそれらの医薬的使用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired